Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||08 Mar 2022||Lorem|
|Rational Vaccines in CRO talks for Phase I/II therapeutic herpes vaccine trial, ICON is ‘frontrunner’; eyes USD 30–60m Series B by 3Q22||28 Jan 2022||William Newton|
|Vaxart engaged with CRO Icon for Phase II trial of COVID-19 vaccine tablet||11 Nov 2021||Reynald Castaneda|
|DreamTec teams up with CROs ICON and WuXi Clinical for Phase I oral COVID-19 vaccine trial eyed for 1Q22||05 Nov 2021||Reynald Castaneda|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer